Today,  21 December 2009, Oslo Børs approved the offering and listing prospectus that  has been prepared by NorDiag ASA in connection with the private placement, through  which  42,000,000 new  shares  will  be  listed  on  Oslo Børs, and the subsequent  repair offering,  where up  to 8,000,000 new  shares in  NorDiag are offered.

The  private placement  has secured  NOK 42 million  in new capital for NorDiag,through  the issue of 42,000,000 shares at a subscription price of NOK 1.00. The new  shares issued in connection with the  private placement will be listed when shares are fully paid and the increase in the share capital is registered in the Norwegian  Register for  Business Enterprises  and the  VPS. Registration of the capital  increase in the Norwegian Register for Business Enterprises and the VPS is expected to take place on or about 22 December 2009.

The  subscription period  for the  new shares  in the subsequent repair offering starts  tomorrow, 22 December 2009, and ends on 12 January 2010, at 17:30 (CET). The  company aims  to raise  up to  NOK 8 million  in fresh  capital through the repair  offering, by issuing  up to 8,000,000 shares  at a subscription price of NOK  1.00. Only those of  the company?s shareholders  as at 25 November 2009 who were  not invited  to participate  in the  private placement have been allocated subscription  rights  in  the  repair  offering.  These  shareholders  have been allocated  2.38323 subscription  rights  for  each  share held as at 25 November 2009 and  will receive prospectus and subscription form. The subscription rights are  tradable and  will be  listed on  Oslo Børs  from and including 22 December 2009.

DnB  NOR Markets has  acted as manager  in the private  placement and the repair offering.

Background for the private placement and the repair offering:

The  purpose of the private  placement and the subsequent  repair offering is to provide  sufficient working capital for the  company until the company is funded through  own operations. The Company expects to reach break-even at EBITDA level in 2011.

By  allocating subscription rights in the  repair offering to those shareholders who  were not invited to  participate in the private  placement, the company hasprovided  the opportunity for  all shareholders to  subscribe shares at the same price as in the private placement.

NorDiag  has delivered a strong top line growth in the second half of 2009, both organically and through the joint venture entered into with Olerup International AB,  while  cost  improvement  programmes  have  resulted in significantly lower costs.

The  restructuring  of  the  company  is  now  complete  and the company is well positioned  for further growth  within its business  areas ? Infectious Diseases and HLA Typing.

Increasing sales of instruments are expected going forward within the Infectious Diseases  segment,  mainly  as  a  result  of  the  good  reception of the Arrow instrument,  which was  launched earlier  this year.  In addition,  the expanded platform  of  sold  instruments  and  influenza  testing  provide a continuously growing platform for reagent sales.

HLA  Typing (transplantation testing)  is a growing  market and NorDiag, through its  subsidiary Olerup International  AB, is well  positioned for taking part in this growth. Through Olerup International AB, NorDiag has also secured access to an expanded distribution network for the Arrow instrument.

The   offering   and   listing   prospectus  is  available  at:  www.nordiag.com

Contact:      
CEO Mårten Wigstøl  - Phone: +47 911 65775
CFO Tone Kvåle       - Phone: +47 915 19576

Read the notice in Norwegian here.